PBAC's latest decision on Pcv15: Recommended with restriction (2021). Considered for Prevention of pneumococcal disease in non-Indigenous adults aged ≥70 years, Indigenous adults aged ≥50 years, and individuals at increased risk of pneumococcal disease aged ≥18 years.
PBAC outcome
Recommended with restriction
2021
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2021
Submissions
1
2021 → 2021
Eligible population
Non-Indigenous adults aged ≥70 years, Indigenous adults aged ≥50 years, and individuals at increased risk of pneumococcal disease aged ≥18 years
Therapy area
Infectious disease
Evidence base
RCT | Single-arm
Primary endpoint
OPA | IgG
Pivotal trial size
652 patients
Key trials
P019, P020, P016, P017, P018, P006, P007
Comparator
13-valent pneumococcal conjugate vaccine (PCV13)
Economic model
Cost-minimisation
ICER note
Cost-minimisation approach used; no ICER calculated